Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 130
- Registration Number
- NCT05235542
- Locations
- 🇨🇳
Shanghai Renji Hospital, Shanghai, China
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 114
- Registration Number
- NCT05229497
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 57
- Registration Number
- NCT05217069
- Locations
- 🇩🇪
Ludwig Maximilians University, Munich, Germany
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT05178745
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 918
- Registration Number
- NCT05152147
- Locations
- 🇦🇷
Hospital de Gastroenterología Dr Bonorino Udaondo, Buenos Aires, Argentina
🇦🇷Fundación Centro de Medicina Nuclear y Molecular ER, Córdoba, Argentina
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Dr. Victor H.F. Lee
- Target Recruit Count
- 30
- Registration Number
- NCT05151588
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT05125055
- Locations
- 🇨🇳
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 830
- Registration Number
- NCT05067283
- Locations
- 🇺🇸
Moffitt Cancer Center ( Site 0261), Tampa, Florida, United States
🇺🇸START Midwest ( Site 0267), Grand Rapids, Michigan, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 0260), Hackensack, New Jersey, United States
CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT05062317
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 153
- Registration Number
- NCT05047991
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.